Search hospitals > Michigan > Dearborn
Henry Ford Medical Center-Fairlane
Claim this profileDearborn, Michigan 48126
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Tumors
95 reported clinical trials
3 medical researchers
Summary
Henry Ford Medical Center-Fairlane is a medical facility located in Dearborn, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Henry Ford Medical Center-Fairlane is involved with conducting 95 clinical trials across 279 conditions. There are 3 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, and Eleanor M. Walker.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
Stage IV
PR positive
Top PIs
Ding WangHenry Ford Hospital5 years of reported clinical research
Expert in Cancer
Studies Non-Small Cell Lung Cancer
49 reported clinical trials
116 drugs studied
Haythem Y. AliHenry Ford Hospital5 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
39 reported clinical trials
103 drugs studied
Eleanor M. WalkerHenry Ford Hospital2 years of reported clinical research
Studies Cancer
Studies Prostate Adenocarcinoma
18 reported clinical trials
58 drugs studied
Clinical Trials running at Henry Ford Medical Center-Fairlane
Non-Small Cell Lung Cancer
Bladder Cancer
Bladder Carcinoma
Squamous Cell Carcinoma
Lung Cancer
Cancer
Renal Cell Carcinoma
Breast Cancer
Urothelial Carcinoma
Prostate Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Targeted Therapy Screening
for Lung Cancer
This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.
Recruiting1 award Phase 2 & 313 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Henry Ford Medical Center-Fairlane?
Henry Ford Medical Center-Fairlane is a medical facility located in Dearborn, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Tumors and other specialties. Henry Ford Medical Center-Fairlane is involved with conducting 95 clinical trials across 279 conditions. There are 3 research doctors associated with this hospital, such as Ding Wang, Haythem Y. Ali, and Eleanor M. Walker.